34
1 Taiwan’ s Premier Biopharma and the future leader in Immuno-Oncology
1
Taiwan’s Premier Biopharma
and the future leader in
Immuno-Oncology
2
Safe Harbor StatementThis presentation contains certain forward-
looking statements.
These forward-looking statements may be identified
by words such as ‘believes’, ‘expects’, ‘anticipates’,
‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
‘future’ or similar expressions or by discussion of,
among other things, strategy, goals, plans or
intentions. Various factors may cause actual results
to differ materially in the future from those reflected in
forward-looking statements contained in this
presentation, among others:
1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and
economic conditions;
3 delay or inability in obtaining regulatory approvals
or bringing products to market;
4 fluctuations in currency exchange rates and
general financial market conditions;
5 uncertainties in the discovery, development or
marketing of new products or new uses of
existing products, including without limitation
negative results of clinical trials or research
projects, unexpected side-effects of pipeline or
marketed products;
6 increased government pricing pressures;
7 interruptions in production
8 loss of or inability to obtain adequate protection
for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.
OBI Pharma cautions that this foregoing list of factors
is not exhaustive. There may also be other risks that
management is unable to predict at this time that may
cause actual results to differ materially from those in
forward-looking statements. You are cautioned not
to place undue reliance on these forward-looking
statements, which speak only as of the date on
which they are made. OBI undertakes no
obligation to update publicly or revise any
forward-looking statements.
Any statements regarding earnings growth is not a
profit forecast and should not be interpreted to mean
that OBI’s earnings or earnings per share for this
year or any subsequent period will necessarily match
or exceed published earnings or earnings per share
forecasts of OBI Pharma, Inc.
3
Mission and History
Leadership
Unique Globo Series Platform – OBI-822
Competitive/Market Analysis
Business Strategy & Vision
Agenda
4
Corporate Introduction
Headquarters Taipei, Taiwan
Founded 29 April 2002
Subsidiaries OBI Pharma USA, Inc.OBI Pharma (HK) LimitedOBI Pharma (Shanghai) Limited
Funds Raised 23 Mar NT$ 6.2B (approx US$ 200M)
Market Capitalization Approx NT$ 60B or US$ 1.9B
Chair Michael Chang, PhD
General Manager Amy Huang
Headcount 84 Total (R&D 54)
Website www.obipharma.com/en
5
OBI Value EvolutionOBI-822
IND US, HK
Dificid wins TFDA
priority review &
exemption from
local BSE
OBI wins Biotech
Industry Award
OBI-822 license movedto OBI
OBIspun-off
OBI-833OBI-868
in-licensed
Foundedas a
wholly-owned
subsidiary of Optimer
Pharma
822-001 P2/P3
trial begins
OBI received
New DrugDeveloper
designationfrom MOEA
Dificid Taiwan market rights
granted
2002 2009 2010 2011 2012 2013 2014822-001
trial entersP3 in
Taiwan
OBI-822IND
Korea,India
OBI-822selectedfor ECFAPioneerProgram
OBI goespublic
Dificid NDA
approval
OBI-822InitiatesOvarian
P2
OBI-868co-developpartnershipMOU signed
OBI-868prototypedeveloped
US Team, China Team
recruited
OBI wins Biotech
Industry Award
822-001enrollmentcompleted
OBI-888pre-clinical
studybegins
OBI-888clone
selectioncompleted
DificidReimburse-
mentapproval
OBI-833IND US
FDAsubmission
NOTE: GREEN
are Corporate
ORANGE are Portfolio
BOLD ORANGE relate to
6
Mission and History
Leadership
Unique Globo Series Platform – OBI-822
Competitive/Market Analysis
Business Strategy & Vision
Agenda
7
Michael Chang, PhD
Founder & Chair
Youe-Kong Shue, PhDVice Chair & Principal Global Clinical Operations & Planning
Amy Huang
General Manager
Global Visionary Leadership
8
Tony YuChief Science Officer
Nathan Chen
Chief Medical Officer & Head of Global Medicines Development
Phoebe Yu
VP Translational Science
David
Hallinan
VP Regulatory Affairs
JS Lai
Senior Director R&D
Jon Liao
Medical Affairs Director
World-class R&D Experience
9
Mitch Che
Chief Operations Officer USA
Joanna Meng
Chief Operations Officer Greater China
Kevin P PoulosChief Commercial Officer
Richard Tseng
VP Quality Assurance
CT Wang
Finance Director
Edward HsiehCMC Director
Highly Experienced Management
10
Mission and History
Leadership
Unique Globo Series Platform – OBI-822
Competitive/Market Analysis
Business Strategy & Vision
Agenda
11
OBI is the onlycompany with a broad
“Globo Series” portfolioin late stage development
Globo Series: Globo H, SSEA-3, SSEA-4
12
Globo Series: New Era in Cancer Therapy
Breast Cancer Tissue Biopsy
Globo H
SSEA-4
Cerββ4α4
β3
Cer
Cerβ3
α2Cer
α3Cer
SSEA-3
globoside
Gb3Cer
Sialic AcidFuc GalNAcGalGlc
60-80%expression
60%expression
90%expression
13
Broad Coverage of Breast Cancer Biomarkers
ER/PR80%
SOURCES:GlobalData;Chang et al. Proc Natl Acad Sci U S A. 2008
Aug 19;105(33):11667-72. Lou et. al., Proc Natl Acad Sci U S A. 2014 Feb
18;111(7):2482-7
Globo Series60~80%
14
Revolution of Cancer TherapyUse of patient’s own immune system to fight
cancer cells
Optimal anti-cancer efficacy
Extended therapeutic effect
COVER IMAGE: Science. Vol. 342 no. 6165 pp. 1432-1433PRN; Reuters; Andrew Baum, Citi Head of Global Healthcare; the Associated Press
Great Impact in ScienceScience Magazine Breakthrough
of the Year 2013Tang Prize: Cancer Immunotherapy
High ExpectationsPredicted to be bestselling-cancer
drugs by CitiBank
Estimated NTD >10 trillion annual
sales by 2023
Cancer Immuno-therapy:A Major Breakthrough in Cancer Therapy
15
Cancer Immunotherapy: “Most Important Advancement in Medical History”
SOURCES: PRN; Reuters; Andrew Baum, Citi Head of Global Healthcare; the Associated Press
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Today Tomorrow
3%
60%
$35 billion a year by
2023
16
Preclinical Indication Pre-Clin P1 P2 P3 NDA
Core ProductsInfectious Disease
Dificid®
fidaxomicinCDAD
Cancer
OBI-822 Breast cancer
OBI-822 Ovarian cancer
OBI-833 Epithelial cancers
OBI-888 Epithelial cancers
Non-core Products
OBI-858 Cosmetics, Migraine
OBI-868 Cancer Diagnostics
OBI Pipeline
17
Induces IgG & IgM targeting Globo Series
KLH
LinkerGlobo H
OBI-822:Innovative Glycoprotein Fully synthetic glycoprotein
Tumor antigen (Globo H) + protein carrier
Induced a robust antibody response
Co-injected 821
+OBI-821:Potent Adjuvant Saponin-based adjuvant
Increases the antigenic response
Introducing OBI-822:A Novel Active Immunotherapy for Cancer
20
OBI-822/821Double-blind, Randomized
Controlled Trial Phase 2/3 of Active Immunotherapy with Globo H-KLH
in Subjects with MetastaticBreast Cancer
Enrollment target reachedon 21 July 2014
